Form 13-F position report

CEREVEL THERAPEUTICS HLDNG

Reported by PERCEPTIVE ADVISORS LLC

CERE CUSIP 15678U128 Manager CIK 0001224962

Reported 5,086,727 shares, up 443,632 (9.6%) from the prior quarter.

Reported value 26.1%; share count 9.6% vs. the prior quarter.

Added
% of reported 13F value 2.18% This manager · Q3 2021
Shares 5,086,727 Quarter-end amount reported
Reported value $150,058,000 Fair value at quarter end
Consecutive quarters held 4 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 150058000
2021-12-31 164911000
2022-03-31 178086000
2022-06-30 134493000
2022-09-30 184021000
2022-12-31 205379869
2023-03-31 158851021
2023-06-30 320709759
2023-09-30 220229445
2023-12-31 464924183
2024-03-31 456299409
2024-06-30 441402480
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for CEREVEL THERAPEUTICS HLDNG held by PERCEPTIVE ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -10,794,876 (-100.0%) 0 $0 2024-11-14
Q2 2024 Unchanged 10,794,876 0 (0.0%) 10.63% $441,402,480 2024-08-14
Q1 2024 Reduced 10,794,876 -170,317 (-1.6%) 7.98% $456,299,409 2024-05-15
Q4 2023 Added 10,965,193 +876,808 (8.7%) 10.38% $464,924,183 2024-02-14
Q3 2023 Unchanged 10,088,385 0 (0.0%) 7.35% $220,229,445 2023-11-14
Q2 2023 Added 10,088,385 +3,576,658 (54.9%) 9.28% $320,709,759 2023-08-14
Q1 2023 Unchanged 6,511,727 0 (0.0%) 4.69% $158,851,021 2023-05-15
Q4 2022 Unchanged 6,511,727 0 (0.0%) 5.77% $205,379,869 2023-02-14
Q3 2022 Added 6,511,727 +1,425,000 (28.0%) 5.34% $184,021,000 2022-11-14
Q2 2022 Unchanged 5,086,727 0 (0.0%) 4.21% $134,493,000 2022-08-15
Q1 2022 Unchanged 5,086,727 0 (0.0%) 3.57% $178,086,000 2022-05-16
Q4 2021 Unchanged 5,086,727 0 (0.0%) 2.54% $164,911,000 2022-02-14
Q3 2021 Added 5,086,727 +443,632 (9.6%) 2.18% $150,058,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

109 managers reported CEREVEL THERAPEUTICS HLDNG for Q3 2021.

Managers reporting CEREVEL THERAPEUTICS HLDNG in Q3 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bain Capital Investors LLC Unchanged 60,632,356 0 21.09% $1,788,655,000 4 qtrs
FMR LLC Added 18,806,629 +9,969,568 0.04% $554,796,000 4 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 5,840,731 +2,513,320 0.02% $172,302,000 4 qtrs
PERCEPTIVE ADVISORS LLC This report Added 5,086,727 +443,632 2.18% $150,058,000 4 qtrs
VANGUARD GROUP INC Added 4,693,159 +1,168,443 < 0.01% $138,448,000 4 qtrs
BlackRock Inc Added 3,363,278 +710,720 < 0.01% $99,217,000 4 qtrs
ALKEON CAPITAL MANAGEMENT LLC Added 3,126,435 +480,000 0.16% $92,230,000 4 qtrs
FEDERATED HERMES INC Added 3,113,333 +1,163,333 0.17% $91,843,000 4 qtrs
STATE STREET CORPORATION Added 2,161,772 +852,253 < 0.01% $63,772,000 3 qtrs
Artal Group S A Reduced 1,800,000 -200,000 1.19% $53,100,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 15, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
5,086,727
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.